Kyntra Bio (LTS:0IL8) Total Receivables: $9.04 Mil (As of Mar. 2026)


LTS:0IL8 Kyntra Bio Inc LTS:0IL8
50 GF Score
Price $7.45
GF Value $5.70
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Total Receivables?

Kyntra Bio LTS:0IL8 -1.94% 50 Total Receivables is $9.04 Mil as of Mar. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 50/100 and a GF Value™ of $5.70 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Kyntra Bio's Total Receivables for the quarter that ended in Mar. 2026 was $9.04 Mil.

Kyntra Bio Total Receivables Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Total Receivables Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.40 16.30 33.62 28.98 4.22

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.14 10.12 4.22 9.04
LTS:0IL8
50GF Score
Kyntra Bio Inc LTS:0IL8
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $9.04 Mil mean?
Kyntra Bio (LTS:0IL8) has a Total Receivables of $9.04 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's Total Receivables too high?
Kyntra Bio's current Total Receivables is $9.04 Mil. Overall, Kyntra Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Total Receivables compare to TVGN and PSTV?
Kyntra Bio's Total Receivables of $9.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Total Receivables is $9.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.70, compared to a current price of $7.45 — trading 30.8% above its estimated fair value. The current Total Receivables is $9.04 Mil. Kyntra Bio's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Total Receivables is $9.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $7.45 is trading 30.8% above its estimated GF Value™ of $5.70. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for LTS:0IL8:

  • Total Receivables: $9.04 Mil
  • GF Value™: $5.70 vs. price of $7.45 (30.8% above fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score

Get the complete analysis for LTS:0IL8

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price
$5.70
GF Value